-
Mashup Score: 5
Andrea hosts Jessica Hawley and Aleksandar Obradovic to discuss their study, published in Cancer Cell, which explores the effects of combining Anti-PD-1 immunotherapy with Androgen Deprivation Therapy (ADT) in metastatic castration-sensitive prostate cancer. The research, part of the PRIME-CUT Study, used advanced techniques like single-cell RNA sequencing and quantitative immunofluorescence to…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet
-
Mashup Score: 5
Andrea hosts Jessica Hawley and Aleksandar Obradovic to discuss their study, published in Cancer Cell, which explores the effects of combining Anti-PD-1 immunotherapy with Androgen Deprivation Therapy (ADT) in metastatic castration-sensitive prostate cancer. The research, part of the PRIME-CUT Study, used advanced techniques like single-cell RNA sequencing and quantitative immunofluorescence to…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Combination therapy jolts 'Exhausted' immune cells awake to attack tumors in patients with #mCSPC. @JessicaHawleyMD @UWMedicine & Aleksandar Obradovic, MD @ColumbiaMed join @AndreaMiyahira @PCFnews to discuss their work published in @Cancer_Cell > https://t.co/aVqmXOlzmT https://t.co/p0m5qyUMNg
-
-
Mashup Score: 5
Andrea hosts Jessica Hawley and Aleksandar Obradovic to discuss their study, published in Cancer Cell, which explores the effects of combining Anti-PD-1 immunotherapy with Androgen Deprivation Therapy (ADT) in metastatic castration-sensitive prostate cancer. The research, part of the PRIME-CUT Study, used advanced techniques like single-cell RNA sequencing and quantitative immunofluorescence to…
Source: www.urotoday.comCategories: General Medicine News, General NewsTweet-
Combination therapy jolts 'Exhausted' immune cells awake to attack tumors in patients with #mCSPC. @JessicaHawleyMD @UWMedicine & Aleksandar Obradovic, MD @ColumbiaMed join @AndreaMiyahira @PCFnews to discuss their work published in @Cancer_Cell > https://t.co/aVqmXOlzmT https://t.co/p0m5qyUMNg
-
-
Mashup Score: 0
Rashid Sayyid and Zach Klaassen discuss a study published in the Annals of Oncology, which delves into the clinical and transcriptomic heterogeneity of metastatic castration-sensitive prostate cancer (mCSPC). The study reveals important differences in patient prognosis based on disease volume and timing of metastases, with the worst prognosis found in synchronous high volume patients. The…
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Transcriptomic and clinical heterogeneity in #mCSPC: Unraveling the molecular landscape. @RKSayyid @UofT & @zklaassen_md @GACancerCenter join in this UroToday #JournalClub discussion > https://t.co/eQoYGf77a9 @Annals_Oncology https://t.co/X1ffHtYpmz
-
-
Mashup Score: 0TITAN Subgroup Analysis Examines Effect of Apalutamide for mCSPC - 8 month(s) ago
The phase 3 TITAN study assigned patients with metastatic castration-sensitive prostate cancer (mCSPC) to apalutamide or placebo in conjunction with androgen deprivation therapy (ADT) to determine if the addition of the drug would improve progression-free survival and overall survival (OS). The protocol-defined and ad-hoc analyses evaluated clinical outcomes of patients who had received apalutamide 240 mg daily (n=525) or placebo (n=527) alongside ADT. Subgroups were created based on volume (high:
Source: guoncologynow.comCategories: Latest Headlines, Partners & KOLsTweet-
A subgroup analysis of the phase 3 TITAN study has assessed the effect of #apalutamide treatment on patients with #mCSPC to determine if disease burden in patients can predict treatment outcomes. Read more: https://t.co/pgL3D7iqF1 https://t.co/QmIXHuJgyt
-
-
Mashup Score: 0
Prostate radiotherapy added to intensified systemic therapy for de novo low-volume mCSPC decreases the risk of radiographic disease progression.
Source: Cancer Therapy AdvisorCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Adding prostate radiotherapy to intensified systemic therapy improves outcomes in de novo metastatic castration-sensitive #prostatecancer with low metastatic burden. Presented at @ASCO #ASCO23. https://t.co/VaarAa7UAp #mCSPC
-
-
Mashup Score: 0
ASCO 2023 results from the phase III PEACE-1 trial, prostate irradiation in men with de novo low-volume metastatic castrate-sensitive prostate cancer (mCSPC), PEACE consortium, Prostate Cancer Consortium in Europe.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Prostate irradiation in men with de novo, low-volume #mCSPC: Results of #PEACE1, a phase 3 randomized trial with a 2x2 design. Presented by @AlbertoBossial @GustaveRoussy. #ASCO23 written coverage by @RKSayyid > https://t.co/9TKz4pFGSG #ProstateCancer @ASCO https://t.co/ke1rQ2U9Ct
-
-
Mashup Score: 9ASCO 2023: The Role of Volume of Disease for Treatment Selection in Patients with mCSPC: A Living Meta-Analysis - 11 month(s) ago
ASCO 2023, prostate cancer, metastatic castration sensitive prostate cancer (mCSPC), ARASENS trial, docetaxel, androgen pathway inhibitor, ENZAMET trial, PEACE-1 trial, doublet therapy for prostate cancer, triplet therapy for prostate cancer.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
The role of volume of disease for treatment selection in patients with #mCSPC: A living meta-analysis. Presented by @SyedArsalanN @MayoClinic. #ASCO23 written coverage by @zklaassen_md @GACancerCenter > https://t.co/h4ADAnNAB8 @ASCO https://t.co/h8JzpPyNZq
-
-
Mashup Score: 2
ASCO 2023 results from CASCARA, quadruplet therapy with cabazitaxel/carboplatin plus abiraterone and ADT in patients with high-volume metastatic castrate-sensitive prostate cancer (mCSPC), CHAARTED high-volume mCSPC.
Source: www.urotoday.comCategories: General Medicine News, Latest HeadlinesTweet-
Early results from #CASCARA: A phase 2 study of cabazitaxel/carboplatin + abiraterone in high-volume metastatic castrate-sensitive #ProstateCancer #mCSPC. Presented by @charlesryanmd @PCFnews. #ASCO23 written coverage by @RKSayyid @UofT > https://t.co/Jx7vTE6F2R @ASCO https://t.co/kjTVfp0hh5
-
-
Mashup Score: 0
A new apalutamide tablet has become available for oncologists in the United States who treat non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer.
Source: Targeted OncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Apalutamide is now available in US in a 240 mg once-daily tablet for the treatment of patients with #nmCRPC and #mCSPC. #pcsm #FDA | @neerajaiims @huntsmancancer https://t.co/cuOo4nm9HV https://t.co/wN5hkbJ17i
-
Combination therapy jolts 'Exhausted' immune cells awake to attack tumors in patients with #mCSPC. @JessicaHawleyMD @UWMedicine & Aleksandar Obradovic, MD @ColumbiaMed join @AndreaMiyahira @PCFnews to discuss their work published in @Cancer_Cell > https://t.co/aVqmXOlzmT https://t.co/p0m5qyUMNg